Suchergebnisse - "Osiyemi, Olayemi"

PubPharm (39)

1

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide : 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

enthalten in: The lancet. HIV | 2024

von Mills, A. | Rizzardini, G. | Ramgopal, M. | +13

2

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2024

von De Wit, S. | Bonnet, F. | Osiyemi, O. | +14

3

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

4

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19 : a randomized, controlled, phase II trial

enthalten in: EClinicalMedicine | 2023

von Jagannathan, P. | Chew, K. | Giganti, M. | +114

5

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

enthalten in: The New England journal of medicine | 2023

von Holland, T. | Cosgrove, S. | Doernberg, S. | +96

CommentIn: N Engl J Med. 2023 Dec 28;389(26):2498. - PMID 38157514

6

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR) : a randomised, open-label, phase 3b, non-inferiority trial

enthalten in: The lancet. HIV | 2023

von Ramgopal, M. | Castagna, A. | Cazanave, C. | +22

CommentIn: Lancet HIV. 2023 Sep;10(9):e558-e559. - PMID 37567204

7

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV : week 52 results of a phase 2/3 trial

enthalten in: The lancet. HIV | 2023

von Ogbuagu, O. | Segal-Maurer, S. | Ratanasuwan, W. | +55

CommentIn: Lancet HIV. 2023 Aug;10(8):e486-e487. - PMID 37451298

8

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1) : Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Llibre, J. | Brites, C. | Cheng, C. | +14

CommentIn: Int J Antimicrob Agents. 2023 Aug;62(2):106839. - PMID 37160239

9

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1 : Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Osiyemi, O. | De Wit, S. | Ajana, F. | +14

CommentIn: Int J Antimicrob Agents. 2023 Aug;62(2):106839. - PMID 37160239

10

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection : Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

enthalten in: Open forum infectious diseases | 2022

von Coutre, S. | Barnett, C. | Osiyemi, O. | +9